Marimed Inc: chief commercial officer Ryan Crandall exercised 32,812 shares

What happened

• The filing reports that Ryan Crandall, chief commercial officer, had derivative/RSU activity on Oct 15, 2026: a conversion or exercise of 32,812 shares at $0.00 per share (total $0) and a second derivative entry for 32,812 shares at $0.00 (derivative, disposed). The filing also reports 9,631 shares were withheld to satisfy tax withholding at $0.06 per share for $578.

Key details

• Transaction date(s) and price(s): Oct 15, 2026; derivative conversions at $0.00 per share; tax withholding at $0.06 per share for $578.
• Shares owned after the transaction: the filing does not report shares owned after the transactions.
• Footnotes: F1 — RSUs convert to common stock on a one-for-one basis. F2 — shares were withheld by the issuer to satisfy tax withholding obligations. F3 — the RSUs were granted Apr 15, 2026; remaining RSUs under this grant vest 32,813 on Jan 15, 2027 and 32,812 on Apr 15, 2027.
• Filing date and timeliness: Form 4 filed on Oct 15, 2026; no late filing indicated in the filing.

Why it may matter

• The filing shows an RSU conversion/derivative exercise and a share withholding to cover taxes (a share withholding, not an open-market sale).
• This filing does not show why the insider traded or why the company acted.